Welcome to our dedicated page for Vireo Growth news (Ticker: VREOD), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vireo Growth's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vireo Growth's position in the market.
Vireo Growth (CSE: VREO, OTCQX: VREOF) will hold a conference call on Tuesday, August 11, 2026, at 8:00 a.m. Eastern Time to discuss its business strategy and second quarter 2026 financial results. The results will be released in a press release before the call.
Management will host the call with a question-and-answer session. Investors can join by dialing the toll-free number +1 833 461 5787 using Meeting ID 596468752, or via a live audio webcast in the Events & Presentations section of Vireo Growth’s investor relations website.
Vireo Growth (CSE: VREO, OTCQX: VREOF) entered four definitive Securities Purchase Agreements to acquire all membership interests of FarmaceuticalRx LLC, FarmaceuticalRx 2 LLC, CAOH LLC and Canoe Hill Ohio, plus certain subsidiaries. The Ohio businesses comprise eight dispensaries, a cultivation and processing facility, and related real estate, creating a vertically integrated platform in Ohio.
The aggregate purchase price is expected to be about $208 million, paid via roughly 11 million subordinate voting shares issued in three tranches over up to 180 days, with performance-based clawback on up to 25% of shares. Closing is targeted for Q4 2026, subject to regulatory approvals and customary conditions. After completing these and previously announced deals, Vireo expects to operate in 16 states with approximately 270 dispensaries. The transactions are a related party transaction under MI 61-101 due to CEO John Mazarakis’ interest in CAOH; he disclosed his conflict and recused himself, and Vireo plans to rely on valuation and minority approval exemptions.
Vireo Growth (CSE: VREO, OTCQX: VREOF) agreed to acquire all outstanding equity of Planet 13 Holdings (CSE: PLTH, OTCQX: PLNH) via a stock-for-stock merger. Each Planet 13 common share will be exchanged for 0.015383618 of a Vireo subordinate voting share, representing a 16.6% premium to Planet 13’s 20-day VWAP and a 24% premium to its July 24, 2026 close.
According to the companies, the deal is expected to add 36 dispensaries, three cultivation/production assets, and up to 2.3 million square feet of Nevada expansion capacity, strengthening Vireo’s Nevada, Florida, and Illinois presence. Pro forma, Vireo expects about 265 dispensaries across 15 states, making it the largest U.S. cannabis operator by dispensary count. Boards of both companies unanimously approved the deal, which remains subject to Planet 13 stockholder, regulatory, and listing approvals. The Merger Agreement includes a US$1.8 million termination fee payable by Planet 13 in specified circumstances, and Planet 13 shares are expected to be delisted following closing.
Vireo Growth (CSE: VREO, OTCQX: VREOF), through subsidiary Vireo Health of Arcadia, entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail operations from subsidiaries of The Cannabist Company across Colorado, Illinois, Massachusetts, New Jersey and West Virginia for up to US$35 million.
Consideration includes up to US$18.75 million in cash at closing and up to US$16.25 million in seller notes, subject to customary adjustments and regulatory approvals. Closings are expected in stages through 2026 and into 2027. The deal could add up to 25 dispensaries, one cultivation site and one production asset, taking Vireo’s pro forma footprint to about 230 dispensaries and operations in 15 states, which Vireo said would create the second-largest U.S. dispensary network. The transaction was unanimously approved by Vireo’s board and Cannabist’s special committee and requires a Canadian Court sale approval and vesting order plus state cannabis regulatory approvals. Cannabist is conducting a court-supervised restructuring under CCAA in Canada, with related Chapter 15 proceedings recognized in the U.S.
Vireo Growth (CSE: VREO, OTCQX: VREOF) has completed its previously announced acquisition of all issued and outstanding membership interests of FarmX, LLC d/b/a PhytoNatural, jointly with Vive Penn, a joint venture between Vireo and Hive Holdings. The deal was executed under a Securities Purchase Agreement referred to as the PhytoNatural Transaction.
The acquisition includes a non-operational Pennsylvania medical cannabis retail permit that, subject to regulatory approvals, authorizes operation of up to six dispensaries in the state. Total consideration was $20.0 million, comprising $8.0 million in cash paid at closing by Vive and approximately $12.0 million to be satisfied by issuing about 645,161 Vireo subordinate voting shares at a deemed price of $18.60 per share, two years after closing, in line with the SPA terms.
Vireo Growth (CSE: VREO, OTCQX: VREOF) engaged Independent Trading Group (ITG) to provide market-making services under Canadian Securities Exchange policies and securities laws.
ITG will trade Vireo subordinate voting shares on the CSE and other venues to maintain a reasonable market and support liquidity objectives, starting around July 7, 2026.
Vireo Growth (CSE: VREO, OTCQX: VREOF; Symbol: VREOD) agreed to acquire, with joint venture Vive Penn, all membership interests of FarmX d/b/a PhytoNatural, which holds a non-operational Pennsylvania retail permit. The deal, valued at about $20 million, supports expansion into Vireo’s 11th state.
Consideration includes $8 million cash at closing from Vive and $12 million in about 645,161 Vireo subordinate voting shares issued two years after closing. The permit could allow up to six medical dispensaries, subject to regulatory approvals and customary closing conditions.
Vireo Growth (CSE:VREO, OTCQX:VREOD) closed its previously announced acquisition of an indirect 49% equity interest in HA-MD, LLC, owner of two Maryland dispensaries. Total consideration is $1.55 million, paid via cash, an interest-bearing promissory note, and issuance of 37,035 shares at a deemed price of $20.25.